ArticleDiagnostics (Basel, Switzerland)2026
Association of Post-Neoadjuvant Chemotherapy MRI and
Burçin Çakan Demirel, Semra Taş, Ayberk Bayramgil, Anıl Yıldız, Şahin Bedir, Nigar Erkoç, Aynur Özen, Merve Tokoçin, Nida Sünnetçi Arıkan, Ali Muhammedoğlu and 2 more
Abstract read
In one paragraphArticle in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Burçin Çakan DemirelDepartment of Medical Oncology, School of Medicine, Istanbul Medipol University, Istanbul Medipol Mega University Hospital, 34214 Istanbul, Türkiye.ORCID 0000-0003-0734-0692 Semra TaşDepartment of Medical Oncology, School of Medicine, Pamukkale University, 20160 Denizli, Türkiye.
Ayberk BayramgilDepartment of Medical Oncology, Umraniye Training and Research Hospital, 34764 Istanbul, Türkiye.ORCID 0000-0003-1782-7808 Anıl YıldızDepartment of Medical Oncology, Basaksehir Cam ve Sakura City Hospital, 34480 Istanbul, Türkiye.ORCID 0000-0002-6402-4445 Şahin BedirDepartment of Medical Oncology, Istinye University, Gaziosmanpaşa Hastanesi, 34240 Istanbul, Türkiye.
Nigar ErkoçDepartment of Radiology, Bağcılar Training and Research Hospital, 34164 Istanbul, Türkiye.ORCID 0000-0002-2162-9284 Aynur ÖzenDepartment of Nuclear Medicine, Bağcılar Training and Research Hospital, 34164 Istanbul, Türkiye.
Merve TokoçinDepartment of General Surgery, Bağcılar Training and Research Hospital, 34164 Istanbul, Türkiye.ORCID 0000-0001-8040-300X Nida Sünnetçi ArıkanDepartment of Radiation Oncology, Bağcılar Training and Research Hospital, 34164 Istanbul, Türkiye.ORCID 0009-0002-1678-6354 Ali MuhammedoğluDepartment of Pathology, Bağcılar Training and Research Hospital, 34164 Istanbul, Türkiye.
Yunus Emre AltıntaşDepartment of Medical Oncology, Umraniye Training and Research Hospital, 34764 Istanbul, Türkiye.ORCID 0000-0002-0634-7350 Ahmet BiliciDepartment of Medical Oncology, School of Medicine, Istanbul Medipol University, Istanbul Medipol Mega University Hospital, 34214 Istanbul, Türkiye.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Accurate non-invasive prediction of pathological complete response (pCR) following neoadjuvant chemotherapy (NACT) in breast cancer (BC) remains challenging despite its established prognostic significance.
Indexed as
18F-fluorodeoxyglucose positron emission tomography/computed tomographybreast cancermagnetic resonance imagingmolecular subtypesneoadjuvant chemotherapypathological complete responsesurvival outcomes
Identifiers
PMID41827989
PMCPMC12984864
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390